^
    over2years
    Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohort. (PubMed, BMC Cancer)
    We predict HRD-positive patients across many cancer types and believe both HRD models may generalize to other mechanisms of HRD outside of BRCA loss. HRD-RNA complements DNA-based HRD detection methods, especially for indications with low prevalence of BRCA alterations.
    Real-world evidence • Journal • BRCA Biomarker • Pan tumor
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • PALB2 (Partner and localizer of BRCA2) • CDK12 (Cyclin dependent kinase 12) • BRCA (Breast cancer early onset) • RAD51B (RAD51 Paralog B) • RAD51C (RAD51 paralog C)
    |
    HRD • PALB2 mutation • RAD51 mutation
    |
    Tempus xT Assay • Tempus xE • Tempus xO assay
    3years
    Tempus Announces Six Abstracts Accepted For Poster Presentation at the 2021 San Antonio Breast Cancer Symposium (Businesswire)
    "Tempus...today announced six abstracts accepted for poster sessions at the 2021 San Antonio Breast Cancer Symposium (SABCS) taking place December 7 - 10. The presented findings highlight the unique insights that Tempus’ data and smart diagnostics generate to advance breast cancer research."
    Preclinical
    |
    Tempus xT Assay • Tempus xE • Tempus xO assay
    |
    istisociclib (KB-0742)
    3years
    Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms. (PubMed, Am J Surg Pathol)
    In one case, none of 20 pathologists recognized a tumor with BRAF and TERT promoter mutations associated with fatal outcome as a conventional melanoma when only limited clinical information was provided, whereas 60% of pathologists correctly diagnosed this case when genomic information was also available. There was also a significant improvement in agreement of which lesions should be classified in the Spitz category/WHO Pathway from an average Cohen κ of 0.360 (SE=0.00921) to 0.607 (SE=0.0232) with genomics.
    Journal • Next-generation sequencing
    |
    BRAF (B-raf proto-oncogene) • TERT (Telomerase Reverse Transcriptase)
    |
    BRAF mutation • TERT mutation • TERT promoter mutation
    |
    Tempus xO assay
    3years
    Tumor Mutational Burden in Histiocytic Neoplasms (ASH 2021)
    Our results suggest a low likelihood of response among histiocytic disorders using immune checkpoint inhibitors. Further exploration among malignant histiocytoses (HS and Langerhans cell sarcoma) is warranted given our findings of higher TMB compared with other histiocytic neoplasms.
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden)
    |
    TMB-H • TMB-L
    |
    Tempus xT Assay • Tempus xO assay